Phase 1 · Exenatide

NCT03645408 trial results

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Alcohol Consumption (standard drink units (SDUs)), 2 hours. Exenatide Injection: 0.93; Sham Injection (Placebo): 2.78.

Participants
8
Status
terminated
Completed
2021-07-01
Sponsor
Boston Medical Center

As posted on ClinicalTrials.gov (NCT03645408), updated at source Feb 9, 2022. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT03645408 measured first

Alcohol Consumptionstandard drink units (SDUs) · 2 hours · mean
Exenatide Injectionn=3Sham Injection (Placebo)n=3
0.93(0.87)2.78(2.66)
Side effects by arm

Side effects in NCT03645408

Percent of participants affected, Up to 38 days. The most common events the registry lists.

EventExenatideSham Injection (Placebo)
Any serious event0%0%
Pre-drug injection anxiety0%33.3%
Nausea33.3%0%
The trial

How NCT03645408 was run

A double-blind, randomized, placebo-controlled, crossover design trial was used to test the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol. The specific objective of this research was to determine whether exenatide has effects on alcohol consumption.

  • Exenatide then Placebo: This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a 5 mcg dose of immediate release exenatide on the day of the first alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Subjects in this arm then received a sham injection on the day of the second alcohol self-administration...
  • Placebo then Exenatide: This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a sham injection on the day of the first alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Subjects in this arm then received a 5 mcg dose of immediate release exenatide on the day of the second alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to...
Who could join the trial

Inclusion Criteria: 1. 21-55 years of age. 2. Able to verify age with a state or federal picture identification. 3. Exceeds safe weekly drinking limits \[4 standard drink units (SDUs) for women or 21 SDUs for men per week\] 4. Reports at least one episode of binge drinking (\>3 SDUs for women, \>4 SDUs for men) an average of once per week in the four weeks prior to baseline screening. 5. Meets Diagnostic And Statistical Manual Of Mental Disorders, Fifth Edition (DSM-5)criteria for mild alcohol use disorder or greater severity. Exclusion Criteria: 1. Seeking treatment for alcohol problems. 2. Clinical Institute Withdrawal Assessment at ≥10 3. DSM-5 diagnosis of current major depression, bipolar disorder, schizophrenia, bulimia/anorexia, dementia, or a substance use disorder other than alcohol, nicotine, marijuana or caffeine. 4. If female, pregnant, nursing, have plans to become pregnant. 5. If female, does not agree to use an accepted form of birth control. 6. Has a medical contraindication to the use of exenatide. 7. Has medical or mental condition for which further alcohol exposure at the planned dose range would be contraindicated. 8. Current risk of suicidality (MINI suicidality score greater than 8 (low risk) or Yes to the ideation question #4 of the C-SSRS). 9. BMI is less than 18 or greater than or equal to 30. 10. History of diabetes. 11. Baseline hemoglobin A1c ≥ 6.5% 12. Baseline non fasting glucose \>200 13. Significantly elevated serum lipase levels. 14. Impaired renal function (GFR \<80 mL/min). 15. Pancreatitis, gastroparesis or other severe gastrointestinal disease. 16. Has had gastric bypass surgery 17. Subject is currently taking warfarin. 18. Has received alcohol counseling or other non-pharmacologic intervention to treat AUD in the past 90 days. 19. Has taken medications that are used to treat alcohol use disorder (AUD) in the past 90 days. 20. Subjects with a history of thyroid cancer or other thyroid disease. 21. Has urine toxicology results positive for cocaine, opioids, amphetamines, buprenorphine, methadone, or methamphetamines. 22. Prior history of anaphylaxis or angioedema with another GLP-1 receptor agonist. 23. Prior use of exenatide 24. Liver function values AST or ALT are twice the normal limit 25. Unable to comfortably abstain from nicotine for a period of 8 hours. 26. Has Chronic obstructive pulmonary disease (COPD), history of solid organ transplant, sickle cell disease, severe heart disease or other health condition for which exposure to COVID-19 represents an unreasonable risk as determined by the study staff physician using accepted COVID-19 guidance (e.g. Centers for Disease Control, etc.). 27. Subject has prior history of Drug-induced thrombocytopenia

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.